TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly. Cramer says Celgene, which has pulled back recently, could earn $16 a share as soon as 2017. Seattle Genetics could have the largest drug pipeline of any drugmaker that's not part of the big four.

At the time of publication, Cramer was long ___.

More from Video

Video: This One Mathematical Concept Can Make You a Millionaire

Video: This One Mathematical Concept Can Make You a Millionaire

AAP Exclusive: Nvidia is Tied to Crypto and That's Bad

AAP Exclusive: Nvidia is Tied to Crypto and That's Bad

Video: Abercrombie & Fitch Shares Surged 57% So Far This Year

Video: Abercrombie & Fitch Shares Surged 57% So Far This Year

Video: Why It's Key to Invest in Stocks Even If You Have Student Loan Debt

Video: Why It's Key to Invest in Stocks Even If You Have Student Loan Debt

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs